Ricky McFaline-Figueroa Lab at NYU
@mcfalinelabnyu.bsky.social
Physician-scientist exploring the cancer biology of gliomas and primary CNS lymphoma to improve patient outcomes. Opinions are my own.
Out now in Nature Communications www.nature.com/articles/s41...
Neoadjuvant anti-PD1 immunotherapy for surgically accessible recurrent glioblastoma: clinical and molecular outcomes of a stage 2 single-arm expansion cohort - Nature Communications
Glioblastoma is resistant to immune-checkpoint inhibitors. In this study, the authors report the results of an expansion cohort (n = 25) of a randomized testing neoadjuvant plus adjuvant pembrolizumab...
www.nature.com
January 27, 2025 at 3:59 AM
Out now in Nature Communications www.nature.com/articles/s41...
Had a wonderful time @neuroonc.bsky.social annual meeting, speaking on the pharmacodynamic effects of neodajuvant pembrolizumab academic.oup.com/neuro-oncolo...
November 25, 2024 at 5:21 PM
Had a wonderful time @neuroonc.bsky.social annual meeting, speaking on the pharmacodynamic effects of neodajuvant pembrolizumab academic.oup.com/neuro-oncolo...